During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

CVS Health Corp (NYSE:CVS)

  • Dividend Yield: 3.05%
  • UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $126 to $118 on Sept. 3, 2026. This analyst has an accuracy rate of 71%.
  • Argus Research analyst Steve Silver maintained a Buy rating and raised the price target from $104 to $114 on Aug. 19, 2026. This analyst has an accuracy rate of 67%.
  • Recent News: Aetna, a healthcare subsidiary of CVS Health, expanded its prior authorization bundles across all cancer types for members in eligible Medicaid states starting Sept. 1.
  • Benzinga Pro’s real-time newsfeed alerted to latest CVS news.

Viatris Inc (NASDAQ:VTRS)

  • Dividend Yield: 2.79%
  • Piper Sandler analyst David Amsellem maintained a Neutral rating and raised the price target from $12 to $13 on Sept. 16, 2026. This analyst has an accuracy rate of 80%.
  • Leerink Partners analyst Daniel Clark initiated coverage on the stock with an Outperform rating and a price target of $20 on Sept. 9, 2026. This analyst has an accuracy rate of 55%.
  • Recent News: On Sept. 16, Viatris received Japan approval for WAKIX in treating excessive daytime sleepiness linked to sleep apnea and narcolepsy.
  • Benzinga Pro’s real-time newsfeed alerted to latest VTRS news

Medtronic PLC (NYSE:MDT)

  • Dividend Yield: 3.17%
  • UBS analyst Priya Sachdeva maintained a Buy rating and raised the price target from $100 to $110 on Sept. 3, 2026. This analyst has an accuracy rate of 66%.
  • Truist Securities analyst Richard Newitter maintained a Hold rating and boosted the price target from $86 to $99 on Sept. 2, 2026. This analyst has an accuracy rate of 66%
  • Recent News: On Sept. 16, Medtronic announced the FDA clearance for LigaSure RAS Maryland instrument on the Hugo RAS system.
  • Benzinga Pro’s real-time newsfeed alerted to latest MDT news

Photo via Shutterstock